Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide

Liubao P, Xiaomin W, Chongqing T, Karnon J, Gannong C, Jianhe L, Wei C, Xia L, Junhua C

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.2165/11314750-000000000-00000

Indexing Status
Subject indexing assigned by NLM

MeSH
Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Breast Neoplasms /economics /therapy; Chemotherapy, Adjuvant /economics; China; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclophosphamide /administration & dosage; Doxorubicin /administration & dosage; Female; Humans; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Taxoids /administration & dosage

AccessionNumber
22009103784

Date bibliographic record published
04/08/2010